AACR 2019 -- Ovarian cancer (OC) is a gynecological malignancy with a high mortality rate of over 14,000 deaths annually in the U.S. Even though ~80% of OC patients initially go into remission after first line treatment (surgery and chemotherapy), more than 60% relapse within 16-18 months.

AACR 2019 -- Radiation therapy (RT) is a highly utilized clinical treatment modality with more than 50% of all cancer patients receiving some type of radiotherapy during the course of their illness. Appropriate systems and models to test preclinical radiation combinations are needed.

AACR 2019 -- Glioblastoma multiforme (GBM) is a fast-growing, aggressive type of central nervous system tumor that forms on the supportive tissue of the brain. It is the most common primary brain tumor.

AACR 2019 -- With the drive in oncology to develop molecules targeting the immune system, there is a need for reliable and well-characterized preclinical models. Orthotopic modeling is becoming increasingly employed in preclinical development as it is posited to have improved clinical translatability compared to subcutaneous implantation.

TIGIT inhibits T and NK cell function by binding CD155 and CD112, which are upregulated on tumor cells. SGN-TIGIT is fully human anti-TIGIT monoclonal antibody (mAb) that has equivalent affinity for human, murine and cynomolgus TIGIT and blocks TIGIT ligand binding. SGN-TIGIT mediates ADCC to preferentially deplete Tregs in ex-vivo PBMC cultures.